

CV Date

10/10/2023

Part A. PERSONAL INFORMATION

First Name *	Antoni		
Family Name *	Bayés Genís		
Sex *	Male	Date of Birth *	
ID number Social Security, Passport *		Phone Number *	
URL Web	www.icor.cat		
Email Address	abayes.germanstrias@gencat.cat		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0002-3044-197X	
	Researcher ID	C-4002-2015	
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Director of Heart Institute (iCor)		
Starting date	2015		
Institution	INSTITUT CATALA DE LA SALUT DE BARCELONA GENERALITAT DE CATALUNYA		
Department / Centre			
Country	Spain	Phone Number	(+0034) 934 65 12 00 - 3743
Keywords			

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2008 - 2023	Full Professor / Universitat Autònoma de Barcelona
2017 - 2019	Vice Dean for Students and Mobility Programs / AUTONOMOUS UNIVERSITY OF BARCELONA (UAB)
2009 - 2010	Director of the Heart Failure Unit / HOSPITAL DE LA SANTA CREU I SANT PAU / Spain
2001 - 2009	Deputy Doctor / HOSPITAL DE LA SANTA CREU I SANT PAU
2003 - 2008	Associated Professor / AUTONOMOUS UNIVERSITY OF BARCELONA (UAB)
1998 - 2000	Post-doctoral Researcher / Mayo Clinic and Foundation, Rochester, MN, USA / United States of America
1998 - 1999	Doctor on call / HOSPITAL DE LA SANTA CREU I SANT PAU
1993 - 1997	Resident Doctor / HOSPITAL DE LA SANTA CREU I SANT PAU

A.3. Education

Degree/Master/PhD	University / Country	Year
Master's Degree in Direction of Integrated Health Services	Ramon Llull University of Barcelona	2009
Official Program of Medicine Doctorate	Autonomous University of Barcelona	1998
Specialist in Cardiology	Spanish Ministry of Education	1998
Medicine and Surgery Degree	Autonomous University of Barcelona	1992

A.4. General quality indicators of scientific production

Results obtained from Web of Science: Searching AUTHOR (bayes-genis* OR bayes genis* OR bayes-genis a* OR bayes genis a):

Total Publications: 835

Sum of the Times Cited : 17.311

Sum of Times Cited without self-citations : 15.642

Citing Articles : 13.103

Average Citations per Item: 23,02

h-index : 85

Part B. CV SUMMARY

Dr Antoni Bayes-Genis is chair of the Germans Trias Heart Institute (iCor) and Director of the Cardiology Department at Hospital Universitari Germans Trias i Pujol (Badalona, Spain), Director of the ICREC (Heart Failure and Cardiac Regeneration) Research Program and Full Professor at Autonomous University of Barcelona. He has published over 835 SCI papers with more than 36,999 citations. He has contributed to over 600 national and international conferences in oral format. He is inventor of 10 international patents, Director/Co-director of 20 PhD Thesis and has established several collaboration agreements with biotechnological companies. Dr. Bayés has the GCP certificate dated 05/03/2023. More than 10 years of experience in clinical trials in the field of cardiology, specifically in heart failure.

1- Development of a new interventional technique to rescue myocardium after a heart attack. He has recently demonstrated that biological tissue engineering restores cardiac function in acute and chronic animal model infarcts (Cardiovasc Res. 2011; Int J Cardiol 2011). In the same way, our group have published the first clinical study results in which were analyzed the safety and efficacy of this new procedure in patients with chronic myocardial infarction to coronary revascularization surgery (EBioMedicine 2016).

2- Identification, characterization, electrical conditioning and myocardial implementation of a new source of stem cells from human epicardial fat (J Tissue Eng Regen Med 2015; Biomed Res Int 2015; JMCC 2010). (ES23257-B1). Our group has also studied the cardiac potential and properties of other myocardial stem cells sources such as umbilical cord blood, subcutaneous adipose tissue and bone marrow (Stem Cells Transl Med 2015; Eur J Clin Invest 2014; Stem Cells Dev 2014; Int J Cardiol 2013; PLoS ONE 2012; J Card Fail 2010; Basic Res Cardiol 2010; Eur J Heart Fail 2006; Transplant Proc 005).

3- Development and application of natural and synthetic matrices for cardiac tissue engineering (Tissue Eng Part C Methods 2016; J Tissue Eng Regen Med 2016; Stem Cell Res Ther 2015; Stem Cell Res Ther 2015; Am J Transl Res 2015; Am J Transl Res 2014; Int J Cardiol. 2014).

4- Study of the molecular/celular bases and new biomarkers/treatments for idiopathic dilated cardiomyopathy (J Cardiovasc Transl Res 2016; Int J Cardiol 2014 Dec 20; Int J Cardiol 2014 Oct 20; Atherosclerosis 2013; Nat Rev Cardiol. 2009; Eur J Heart Fail. 2007).

5- Molecular analysis of the effect of hipoxia on cardiac and vascular remodeling (J Mol Cell Cardiol 2015; Arterioscler Thromb Vasc Biol 2013).

6- Development of elastin stent to reduce the risk of restenosis (Development 2003; Trends Cardiovasc Med. 2003). This research was the first to use bioactive stents, widely used in clinical practice today.

7- Human heart chimerism. Pioneers in 2002 to identify the human heart auto-regenerative capacity and the presence of cardiac microchimerism. A summary of the contributions was published, requested by the editor in the scientific journal Nature Clinical Practice CV Medicine

(Nat Clin Pract Cardiovasc Med. 2007; J Heart Lung Transplant. 2005; Eur J Heart Fail. 2004; Cardiovasc Res. 2002).

8- Identification of a new biomarker PAPP-A for an early detection of unstable angina and myocardial infarction. This investigation was published in the journal N Engl J Med (NEJM 2001; 345:1022-9) and generates a patent (US8323913-B2).

9- Characterization of the clinical use of natriuretic peptides for diagnosis, prognosis and monitoring in heart failure. Data generated are now included in clinical guidelines.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper**. 2023. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy.
- 2 **Scientific paper**. 2023. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute <scp>CardioVascular</scp> Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. European journal of heart failure.
- 3 **Scientific paper**. 2023. An update on utilising brain natriuretic peptide for risk stratification, monitoring and guiding therapy in heart failure. Expert review of molecular diagnostics.
- 4 **Scientific paper**. 2023. Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment. European journal of heart failure.
- 5 **Scientific paper**. 2023. Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society. Progress in cardiovascular diseases.
- 6 **Scientific paper**. 2023. Biophysical Tissue Characterization of Ventricular Tachycardia Substrate With Local Impedance Mapping to Predict Critical Sites. JACC. Clinical electrophysiology.
- 7 **Scientific paper**. 2023. Cardiac magnetic resonance outperforms echocardiography to predict subsequent implantable cardioverter defibrillator therapies in ST-segment elevation myocardial infarction patients. Frontiers in cardiovascular medicine.
- 8 **Scientific paper**. 2023. Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients. European heart journal. Acute cardiovascular care.
- 9 **Scientific paper**. 2023. Current and future trial design in refractory cardiogenic shock. European journal of heart failure.
- 10 **Scientific paper**. 2023. Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology.
- 11 **Scientific paper**. 2023. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction. Revista española de cardiología.
- 12 **Scientific paper**. 2023. Endothelial deletion of Wt1 disrupts coronary angiogenesis and myocardium development. Development.
- 13 **Scientific paper**. 2023. Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO-HF trial. European journal of heart failure.
- 14 **Scientific paper**. 2023. Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus. Antioxidants.

- 15 **Scientific paper**. 2023. Frailty and outcomes in heart failure patients from high-, middle- and low-income countries.
- 16 **Scientific paper**. 2023. Global Variations in Heart Failure Etiology, Management, and Outcomes. JAMA.
- 17 **Scientific paper**. 2023. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the <scp>ESC-HFA EORP</scp> Heart Failure Long-Term Registry. European journal of heart failure.
- 18 **Scientific paper**. 2023. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the <scp>DAPA-MODA</scp> study. European journal of heart failure.
- 19 **Scientific paper**. 2023. Interatrial Block Association With Adverse Cardiovascular Outcomes in Patients Without a History of Atrial Fibrillation. JACC. Clinical electrophysiology.
- 20 **Scientific paper**. 2023. Is Dapagliflozin a Cardiac Anti-Aging Drug?. JACC. Heart failure.
- 21 **Scientific paper**. 2023. Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction.
- 22 **Scientific paper**. 2023. Mechanical complications in STEMI: prevalence and mortality trends in the primary PCI era. The Ruti-STEMI registry. Revista española de cardiología.
- 23 **Scientific paper**. 2023. Meteorin-like protein is associated with a higher risk profile and predicts a worse outcome in patients with STEMI. Revista española de cardiología.
- 24 **Scientific paper**. 2023. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Journal of cardiac failure.
- 25 **Scientific paper**. 2023. Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation.
- 26 **Scientific paper**. 2023. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts. Revista española de cardiología.
- 27 **Scientific paper**. 2023. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat. Patient preference and adherence.
- 28 **Scientific paper**. 2023. Performance analysis of a STEMI network: prognostic impact of the type of first medical contact facility. Revista española de cardiología.
- 29 **Scientific paper**. 2023. Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC.
- 30 **Scientific paper**. 2023. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides. JACC. Heart failure.
- 31 **Scientific paper**. 2023. Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry.
- 32 **Scientific paper**. 2023. Quality over quantity: Assessing the need for multiple biomarkers in predicting heart failure outcomes.
- 33 **Scientific paper**. 2023. Recruited macrophages elicit atrial fibrillation.
- 34 **Scientific paper**. 2023. Safety evaluation of smart scales, smart watches, and smart rings with bioimpedance technology shows evidence of potential interference in cardiac implantable electronic devices. Heart rhythm.
- 35 **Scientific paper**. 2023. Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the <scp>VECTOR-HF</scp> trial. European journal of heart failure.
- 36 **Scientific paper**. 2023. Sudden Cardiac Death in Heart Failure: A 20-Year Perspective From a Mediterranean Cohort. Journal of cardiac failure.
- 37 **Scientific paper**. 2023. The Heart Failure Association endorses the 25in25 initiative. European journal of heart failure.
- 38 **Scientific paper**. 2023. Time course, factors related to, and prognostic impact of venoarterial extracorporeal membrane flow in cardiogenic shock. ESC heart failure.

- 39 **Scientific paper**. 2023. Transcatheter Aortic Valve-in-Valve Replacement for Failed Sutureless Aortic Valves. JACC. Cardiovascular interventions.
- 40 **Scientific paper**. 2023. Unlocking the Potential of Natriuretic Peptide Testing in Primary Care: A Roadmap for Early Heart Failure Diagnosis. European journal of heart failure.
- 41 **Scientific paper**. 2023. Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19. Medicina clínica.
- 42 **Scientific paper**. 2023. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. European journal of heart failure.
- 43 **null**. 2023. CA125 for Fluid Overload Monitoring.
- 44 **null**. 2023. Cardiac electronic implantable devices: A call for a new coding system.
- 45 **null**. 2023. Late gadolinium enhancement distribution patterns in non-ischemic dilated cardiomyopathy: Genotype-phenotype correlation.
- 46 **null**. 2023. Reply to the Editor– Safety of wearable bioimpedance monitors for CIED patients remains unknown.
- 47 **null**. 2023. State-of-the-art document on optimal contemporary management of cardiomyopathies.

C.2. Conferences and meetings

- 1 State of the Art and Future Direction in Translational Research. 27th Annual Scientific Meeting of the Japan, JHFS2023. 2023. Japan.
- 2 2023 HF ESC guidelines: The hotlines. 26th Maghrebin Congress of Cardiology & the 43rd Tunisian congress of Cardiology and Cardiovascular Surgery & the 10th Congress of the Association of Cardiovascular Physicians of Sfax. 2023. Tunisia.
- 3 How to sequence, how to up titrate in 2023?. 26th Maghrebin Congress of Cardiology & the 43rd Tunisian congress of Cardiology and Cardiovascular Surgery & the 10th Congress of the Association of Cardiovascular Physicians of Sfax. 2023. Tunisia.
- 4 SGLT2 Inhibitors: Real-Life Experience and Insights. 26th Maghrebin Congress of Cardiology & the 43rd Tunisian congress of Cardiology and Cardiovascular Surgery & the 10th Congress of the Association of Cardiovascular Physicians of Sfax. 2023. Tunisia.
- 5 2023 heart failure guideline recommendations: where do we stand?. ESC Congress 2023. European Society of Cardiology. 2023.
- 6 Obesity and heart failure: diagnostic dilemmas. ESC Congress 2023. European Society of Cardiology. 2023.
- 7 Prognostic role of fragility detection in a heart failure clinic using the vulnerable elders survey scale 13 (VES-13) and a multimodality assessment.. ESC Congress 2023. European Society of Cardiology. 2023.
- 8 The heart failure challenge: a practical approach to heart failure treatment with SGLT2 inhibitors.. ESC Congress 2023. European Society of Cardiology. 2023.
- 9 Use of biomarkers in heart failure. PCHF London Module 1. Royal Brompton and Harefield hospitals. 2023. United Kingdom.
- 10 Biomarkers in Heart Failure. Heart Failure International Forum. Heart Failure Association. 2023. Romania.
- 11 Cardiac rhythm management devices: a cornerstone of heart failure care. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.
- 12 Diabetic cardiomyopathy in heart failure: a new target for therapy. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.
- 13 Early diagnosis of heart failure: the next target. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.
- 14 State of the art: are HFpEF phenotypes, a needed classification?. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.
- 15 Unmet needs in HFpEF diagnosis. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.
- 16 Worsening heart failure: a critical event. Heart Failure 2023. Heart Failure Association. 2023. Czech Republic.

- 17 iSGLT-2 y remodelado cardíaco post-IAM: ¿una nueva oportunidad terapéutica?. Reunión Asociación de Cardiopatía Isquémica y Cuidados Agudos Cardiovasculares. Asociación de Cardiopatía Isquémica y Cuidados Agudos Cardiovasculares. 2023. Spain.
- 18 Biomarkers in the diagnosis and management of heart failure. Heart Failure Program Hybrid 2023. Heart Failure Association. 2023. United Arab Emirates.
- 19 Diabetes and heart failure: two epidemics that collide. Heart Failure Program Hybrid 2023. Heart Failure Association. 2023. United Arab Emirates.
- 20 Biomarkers. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.
- 21 Definition and Epidemiology. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.
- 22 Diabetes, CKD. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.
- 23 Optimization and Titration Before and After Discharge. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.
- 24 Sacubitril/Valsartan. Beta-blockers, Ivabradine and Digoxin. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.
- 25 Universal definition and Phenotypes of Heart Failure. Heart Failure Clinical Practice Update Course. European Heart Failure Association (HFA). 2023. Egypt.

C.3. Research projects and contracts

- 1 **Project.** PMP21/00064, ESTUDIO PROSPECTIVO, ALEATORIZADO, MULTICÉNTRICO, ABIERTO, PARA EVALUAR LA NO INFERIORIDAD DE UNA ESTRATEGIA PERSONALIZADA DE PRECISIÓN PARA LA PREVENCIÓN DE LA MUERTE SÚBITA EN PACIENTES CON MIOCARDIOPATÍA DILATADA NO ISQUÉMICA - ESTUDIO CIBER-SPANISH I. AES 2021- CONVOCATORIA PROYECTOS DE INVESTIGACIÓN DE MEDICINA PERSONALIZADA (ISCIII). (CIBER ENFERMEDADES CARDIOVASCULARES (CIBERCV)). 01/01/2022-31/12/2025. 1.419.465 €.
- 2 **Project.** Inflammatory modulation of STEMI-derived cardiogenic shock with extracellular vesicles (EVs): EV4MI Trial.. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/01/2021-31/12/2024. 646.250 €.
- 3 **Project.** The PERISCOPE Trial. PERIcardial matrix with mesenchymal Stem Cells fOr the treatment of PatiEnts with infarcted myocardial tissue.. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/01/2020-31/12/2024. 837.000 €.
- 4 **Project.** Efficacy of the Adipose Graft Transposition Procedure (AGTP) in patients with a myocardial scar: The AGTP II trial.. Proyectos de Investigación Clínica Independiente en Terapias Avanzadas 2017. Bayes Genis A. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/01/2019-31/12/2024. 330.000 €. Principal investigator.
- 5 **Project.** HR22-00732, Somatic mutations and clonal hematopoiesis as predictors and drivers of heart failure progression (MyoClonal). CaixaResearch Health 2022. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/10/2022-30/09/2024. 79.200 €.
- 6 **Project.** In vitro method for predicting mortality risk in patients suffering from cardiogenic shock. CaixaResearch Validate de la Fundación "la Caixa". (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/09/2021-01/09/2022. 100.000 €.
- 7 **Project.** Evaluation of the anti-arrhythmic and anti-inflammatory protective effects of empagliflozin in a porcine model of myocardial infarction.. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/05/2021-31/03/2022. 163.000 €.
- 8 **Project.** Detection of structural faults in implanted stents through non-invasive techniques of microwave radiation. Caixaimpulse 2020. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/08/2020-31/07/2021. 70.000 €. Call Name: Caixaimpulse Validate 2020 Application Number: CI20-00230 Project Leader: Carolina Gálvez

- 9 **Project.** 2019PROD00122, In vitro method for predicting mortality risk in patients suffering from cardiogenic shock.. Convocatòria d'Indústria del Coneixement 2019. AGAUR CATALUNYA.. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 15/07/2020-15/07/2021. 99.999,21 €.
- 10 **Project.** BIOMarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure. (BIOTOOL-CHF). (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). From 2023. 321.392,5 €. Principal investigator.
- 11 **Project.** Cardiac Organoids for Cell Therapy in a Preclinical Model of Myocardial Infarction. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). From 2023. 337.500 €. Principal investigator.
- 12 **Project.** Study of Personalized Allocation of defibrillators in Non-Ischemic Heart failure (Spanish I). (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). From 01/01/2022.
- 13 **Project.** CIBER - Cardiovascular diseases - Clinical application of biomarkers in the characterization and stratification of myocardial damage as well as in the assessment of biotherapies targeted to the restauration of ventricular function. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). From 22/09/2016.

C.4. Activities of technology / knowledge transfer and results exploitation

- 1 Sabidó Aguade, Eduard; Borràs Ramírez, Eva; Rueda Sobella, Ferran; Bayés Genis, Antonio; Iborra Egea, Oriol; García García, Cosme. 19382126.1 - 1118. IN VITRO METHOD FOR PREDICTING MORTALITY RISK IN PATIENTS SUFFERING FROM SHOCK Spain. 20/02/2019. FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL. Centro de Regulación Genómica.
- 2 PCT/EP2018/075139. STENT MONITORING Spain. 18/09/2018. Universitat de Barcelona.
- 3 Antoni Bayés Genís; Amparo Galan; Jaume Barallat; Josep Lupón Rosés. EP14182846.7. Nepriysin as heart failure prognostic marker 02/03/2016. FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL.
- 4 Antoni Bayes Genis; Aida Lluçà Valldeperas; Carolina Soler Botija; Ramón Bragós Bardia; Francesc Rosell. PCT/EP2016/051258. METHOD FOR CONDITIONING STEM CELLS 21/01/2016. FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL.
- 5 Francesc Rosell; Benjamí Sánchez; Ramón Bragós; Antoni Bayés; Aida Lluçà. PCT/EP2012/061224. METHODS AND DEVICES FOR MECHANICAL AND ELECTRICAL STIMULATION OF STEM CELL MONOLAYER AND 3D CULTURES FOR TISSUE ENGINEERING APPLICATIONS 19/12/2013. FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL.
- 6 Juan Carlos Chaques; Antoni Bayés Genís; Manuel Monleon; Carlos Eduardo Semino; Nicole Zur-Nieden; Philippe Jenny. EP2422823-A1. Bioactive implant Spain. 29/02/2012. Institut Químic de Sarrià.
- 7 Juan Carlos Chaques; Antoni Bayés Genís; Manuel Monleon; Carlos Eduardo Semino; Nicole Zur-Nieden; Philippe Jenny. WO2011134957-A1. BIOACTIVE IMPLANT FOR MYOCARDIAL REGENERATION AND VENTRICULAR CHAMBER RESTORATION 03/11/2011. Institut Químic de Sarrià.
- 8 Antoni Bayés Genís; Dirk Buscher; Jordi Farré; Cristina Prat Vidal; Santiago Roura. ES2325715-B1. New isolated adult stem cell, from fatty mammalian heart tissue, expressing GATA binding protein 4 and/or constitutive form of Cx43, useful for preparing a composition for treating ischemic heart disease and post-myocardial infarction Spain. 04/08/2007. INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU.
- 9 Juan Cinca; Antoni Bayés Genís; Javier Rosell Ferrer. WO2005044103-A1. Sistema multiparamétrico para el diagnóstico de rechazo posttrasplante e inflamación basado en la temperatura y la impedancia eléctrica tisular. Spain. 01/11/2006. Universitat Politècnica de Catalunya.

- 10** David R Holmes; Antoni Bayés Genís; Cheryl A Conover; Robert S Schwartz. US8323913-B2. Marker for inflammatory conditions United States of America. 31/12/2002. Mayo Clinic.
- 11** Allan R Camrud; Antoni Bayes Genis; Robert S Schwartz. US6709449-B2. Stent treatment apparatus and method United States of America. 26/09/2002. Mayo Clinic.